Source:http://linkedlifedata.com/resource/pubmed/id/15033344
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2004-3-22
|
pubmed:abstractText |
Development of suitable imaging ligands to facilitate in vivo characterisation of alpha(2)-adrenoceptors has been limited in its success. In the present study, a series of iodinated derivatives and a fluorinated derivative of the classical alpha(2)-adrenoceptor antagonist, idazoxan, have been evaluated as potential imaging ligands. These compounds are based on the structure of idazoxan but more closely resemble the selective alpha(2)-adrenoceptor antagonists 2-methoxy-idazoxan (RX821002) and 2-ethoxy-idazoxan (RX811059). Preliminary studies, investigating their affinities at alpha(2)-adrenoceptors, using brain membranes prepared from a variety of species, and their ability to antagonise UK14, 304-induced inhibition of twitch in mouse vas deferens highlighted 2-iodopropoxy-idazoxan and 2-fluoroethoxy-idazoxan as the most promising candidates. Further characterisation of these two compounds showed they had a good selectivity for alpha(2)-adrenoceptors compared with imidazoline(2)-binding sites and beta-adrenoceptors. Additional functional studies also showed a lack of intrinsic activity at alpha(2)-adrenoceptors. Following intravenous injection, both compounds were able to cross the blood brain barrier when tested using an ex vivo binding assay. These data show that both 2-iodopropoxy-idazoxan and 2-fluoroethoxy-idazoxan have binding and functional properties suitable for imaging ligands. Further studies using radiolabelled forms of these ligands and a more extensive characterisation of their binding profiles are necessary but these initial evaluations demonstrate their potential.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0028-3908
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
847-55
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:15033344-Adrenergic Antagonists,
pubmed-meshheading:15033344-Adrenergic alpha-2 Receptor Antagonists,
pubmed-meshheading:15033344-Animals,
pubmed-meshheading:15033344-Brain,
pubmed-meshheading:15033344-Diagnostic Imaging,
pubmed-meshheading:15033344-Dose-Response Relationship, Drug,
pubmed-meshheading:15033344-Guinea Pigs,
pubmed-meshheading:15033344-Male,
pubmed-meshheading:15033344-Mice,
pubmed-meshheading:15033344-Protein Binding,
pubmed-meshheading:15033344-Radioligand Assay,
pubmed-meshheading:15033344-Rats,
pubmed-meshheading:15033344-Rats, Wistar,
pubmed-meshheading:15033344-Receptors, Adrenergic, alpha-2
|
pubmed:year |
2004
|
pubmed:articleTitle |
Pharmacological characterisation of novel alpha 2-adrenoceptor antagonists as potential brain imaging agents.
|
pubmed:affiliation |
Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol BS8 1TD, UK.
|
pubmed:publicationType |
Journal Article
|